Zacks Research Has Bullish Estimate for BMRN Q1 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at Zacks Research boosted their Q1 2025 EPS estimates for BioMarin Pharmaceutical in a research note issued on Wednesday, January 8th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $0.61 for the quarter, up from their prior estimate of $0.60. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $2.49 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical’s FY2025 earnings at $2.68 EPS, Q2 2026 earnings at $0.84 EPS and Q3 2026 earnings at $0.89 EPS.

Other analysts have also issued research reports about the stock. Wedbush raised shares of BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Monday, November 4th. Stifel Nicolaus lowered their price target on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a “buy” rating on the stock in a report on Tuesday, September 17th. Scotiabank reduced their price objective on BioMarin Pharmaceutical from $95.00 to $78.00 and set a “sector perform” rating for the company in a report on Tuesday, September 17th. Truist Financial lowered their target price on BioMarin Pharmaceutical from $118.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, September 17th. Finally, Sanford C. Bernstein cut their price target on BioMarin Pharmaceutical from $116.00 to $90.00 and set an “outperform” rating for the company in a research note on Tuesday, September 17th. Seven analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

BioMarin Pharmaceutical Trading Up 0.7 %

Shares of BioMarin Pharmaceutical stock opened at $68.38 on Friday. The firm has a market cap of $13.03 billion, a PE ratio of 40.95, a P/E/G ratio of 0.65 and a beta of 0.29. BioMarin Pharmaceutical has a 1 year low of $61.15 and a 1 year high of $98.23. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The stock has a fifty day moving average price of $65.81 and a 200-day moving average price of $75.23.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.23). BioMarin Pharmaceutical had a net margin of 11.71% and a return on equity of 8.53%. The firm had revenue of $746.00 million during the quarter, compared to analysts’ expectations of $703.37 million. During the same quarter in the prior year, the company earned $0.26 EPS. The business’s revenue for the quarter was up 28.4% on a year-over-year basis.

Insider Activity at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 5,278 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total value of $350,300.86. Following the sale, the executive vice president now directly owns 68,909 shares of the company’s stock, valued at $4,573,490.33. This trade represents a 7.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.85% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. Acadian Asset Management LLC increased its stake in BioMarin Pharmaceutical by 377.5% in the second quarter. Acadian Asset Management LLC now owns 12,113 shares of the biotechnology company’s stock valued at $994,000 after acquiring an additional 9,576 shares during the last quarter. Texas Permanent School Fund Corp purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $2,194,000. Royal London Asset Management Ltd. lifted its position in BioMarin Pharmaceutical by 1.5% in the 2nd quarter. Royal London Asset Management Ltd. now owns 73,287 shares of the biotechnology company’s stock worth $6,034,000 after buying an additional 1,090 shares during the last quarter. Andra AP fonden purchased a new stake in BioMarin Pharmaceutical in the second quarter worth approximately $1,515,000. Finally, Daiwa Securities Group Inc. grew its position in BioMarin Pharmaceutical by 3.2% during the second quarter. Daiwa Securities Group Inc. now owns 16,821 shares of the biotechnology company’s stock valued at $1,385,000 after acquiring an additional 514 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.